论文部分内容阅读
目的:探讨尼洛替尼在伊马替尼耐药的慢性髓系白血病(CML)患者中的疗效及不良反应。方法:9例伊马替尼耐药的CML患者,其中慢性期6例,进展期3例,持续口服尼洛替尼400mg 2次/d,观察其疗效及不良反应。结果:6例CML慢性期患者,5例获得完全血液学反应,2例获得主要细胞遗传学反应;3例CML进展期患者均获得血液学缓解。平均用药时间为18.2个月,其中2例进展期患者因用药仅1个月,尚未进行相关细胞遗传学及分子生物学检测评估疗效。9例患者中8例耐受良好,不良反应多不严重,经对症处理后缓解,仅1例因心脏不良反应停止用药。结论:尼洛替尼对于伊马替尼耐药的CML患者是有效的,且耐受性良好。
Objective: To investigate the efficacy and side effects of nilotinib in patients with imatinib-resistant chronic myelogenous leukemia (CML). Methods: Nine patients with imatinib-resistant CML, 6 patients in chronic phase and 3 in advanced stage, were treated with nilotinib 400 mg twice daily for observing the curative effect and adverse reactions. RESULTS: Of the 6 patients with chronic CML, 5 had complete hematologic response, 2 had major cytogenetic response, and 3 had advanced hematologic response to CML. The average medication time was 18.2 months, of which 2 cases of advanced patients due to medication for only 1 month, not yet related to cytogenetics and molecular biology tests to assess the efficacy. Of the 9 patients, 8 were well tolerated and the adverse reactions were not serious. After symptomatic treatment, only 8 patients were stopped because of adverse cardiac reactions. Conclusion: Nilotinib is effective in patients with CML resistant to imatinib and is well tolerated.